Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ETON Stock Forecast 2026-2027
$25.04
Current Price
$683.20M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ETON Price Targets
+107.7%
To High Target of $52.00
+39.8%
To Median Target of $35.00
+23.8%
To Low Target of $31.00
ETON Price Momentum
-5.0%
1 Week Change
+20.6%
1 Month Change
+74.6%
1 Year Change
+48.1%
Year-to-Date Change
-8.2%
From 52W High of $27.29
+91.3%
From 52W Low of $13.09
📊 TOP ANALYST CALLS
Did ETON Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Eton Pharma is one of their latest high-conviction picks.
Latest ETON Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, ETON has a bullish consensus with a median price target of $35.00 (ranging from $31.00 to $52.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $25.04, the median forecast implies a 39.8% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Swayampakula Ramakanth at HC Wainwright & Co., projecting a 107.7% upside. Conversely, the most conservative target is provided by Madison El-Saadi at B. Riley Securities, suggesting a 23.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ETON Analyst Ratings
3
Buy
0
Hold
0
Sell
ETON Price Target Range
Low
$31.00
Average
$35.00
High
$52.00
Current: $25.04
Latest ETON Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ETON.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 20, 2026 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $35.00 |
| Mar 20, 2026 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $52.00 |
| Mar 20, 2026 | B. Riley Securities | Madison El-Saadi | Buy | Maintains | $31.00 |
| Mar 3, 2026 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $30.00 |
| Mar 2, 2026 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $37.00 |
| May 29, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $35.00 |
| May 16, 2025 | B. Riley Securities | Madison El-Saadi | Buy | Reiterates | $26.00 |
| May 14, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $28.00 |
| Mar 19, 2025 | B. Riley Securities | Madison El-Saadi | Buy | Reiterates | $24.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $33.00 |
| Mar 19, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $26.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $33.00 |
| Jan 10, 2025 | B. Riley Securities | Madison El-Saadi | Buy | Initiates | $21.00 |
| Jan 8, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $18.00 |
| Jan 6, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $17.00 |
| Nov 26, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $15.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $11.00 |
| Oct 28, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $15.00 |
| Oct 4, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $10.00 |
| Oct 4, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $11.00 |
Eton Pharmaceuticals Inc. (ETON) Competitors
The following stocks are similar to Eton Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Eton Pharmaceuticals Inc. (ETON) Financial Data
Eton Pharmaceuticals Inc. has a market capitalization of $683.20M with a P/E ratio of 124.0x. The company generates $79.95M in trailing twelve-month revenue with a -5.8% profit margin.
Revenue growth is +82.7% quarter-over-quarter, while maintaining an operating margin of +21.0% and return on equity of -18.2%.
Valuation Metrics
Market Cap
$683.20M
Enterprise Value
$671.70M
P/E Ratio
124.0x
PEG Ratio
-0.3x
Price/Sales
8.3x
Growth & Margins
Revenue Growth (YoY)
+82.7%
Gross Margin
+61.6%
Operating Margin
+21.0%
Net Margin
-5.8%
EPS Growth
+82.7%
Financial Health
Cash/Price Ratio
+3.8%
Current Ratio
1.6x
Debt/Equity
118.8x
ROE
-18.2%
ROA
+3.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Eton Pharmaceuticals Inc. (ETON) Business Model
About Eton Pharmaceuticals Inc.
What They Do
Develops treatments for rare diseases.
Business Model
The company focuses on acquiring and developing treatments for ultra-rare diseases that are often overlooked by larger pharmaceutical firms. Eton generates revenue through its portfolio of FDA-approved products and utilizes a specialized sales force along with patient support programs to reach eligible patients.
Additional Information
Eton Pharmaceuticals has a range of FDA-approved products targeting conditions such as severe IGF-1 deficiency and adrenal insufficiency. Their late-stage pipeline includes promising candidates for diabetes insipidus and adrenal crisis. The company aims to serve underserved patient populations and is strategically positioned in the orphan drug market segment.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
44
CEO
Mr. Sean E. Brynjelsen
Country
United States
IPO Year
2018
Website
www.etonpharma.comEton Pharmaceuticals Inc. (ETON) Latest News & Analysis
Latest News
Quick Summary
Judith M. Matthews, an experienced pharmaceutical executive, will become the CFO on June 1st.
Why It Matters
Judith M. Matthews’ appointment as CFO signals potential strategic shifts and financial oversight improvements, impacting company performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Eton Pharmaceuticals (ETON) experienced a surge in share price and higher-than-average trading volume, though recent earnings estimate revisions may not lead to continued price increases soon.
Why It Matters
Eton Pharmaceuticals' share surge and increased trading volume indicate heightened investor interest, but the uncertain earnings estimate revisions suggest potential volatility ahead.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Eton Pharmaceuticals (ETON) has passed the "Recent Price Strength" screening, indicating potential for profit as it gains momentum in the stock market.
Why It Matters
Eton Pharmaceuticals' recent price strength indicates positive momentum, suggesting potential for gains. This could attract investors seeking profitable opportunities in active stocks.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Eton Pharmaceuticals, Inc. (ETON) held its Q4 2025 earnings call, discussing financial results and company performance. Further details can be found in the full transcript.
Why It Matters
Eton Pharmaceuticals' Q4 earnings call provides insights into financial performance, future guidance, and strategic direction, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Eton Pharmaceuticals (Nasdaq: ETON) reported its financial results for Q4 2025 on March 19, 2026, focusing on treatments for rare diseases.
Why It Matters
Eton Pharmaceuticals' quarterly financial results indicate its performance and growth potential, impacting stock valuation and investor confidence in the rare disease market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Eton Pharmaceuticals (ETON) reported Q3 earnings of $0.05 per share, missing the Zacks estimate of $0.12. This contrasts with a loss of $0.02 per share in the same quarter last year.
Why It Matters
Eton Pharmaceuticals' earnings miss signals potential operational challenges, impacting investor confidence and stock performance. Comparisons to last year highlight deteriorating financial health.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About ETON Stock
What is Eton Pharmaceuticals Inc.'s (ETON) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Eton Pharmaceuticals Inc. (ETON) has a median price target of $35.00. The highest price target is $52.00 and the lowest is $31.00.
Is ETON stock a good investment in 2026?
According to current analyst ratings, ETON has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $25.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ETON stock?
Wall Street analysts predict ETON stock could reach $35.00 in the next 12 months. This represents a 39.8% increase from the current price of $25.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Eton Pharmaceuticals Inc.'s business model?
The company focuses on acquiring and developing treatments for ultra-rare diseases that are often overlooked by larger pharmaceutical firms. Eton generates revenue through its portfolio of FDA-approved products and utilizes a specialized sales force along with patient support programs to reach eligible patients.
What is the highest forecasted price for ETON Eton Pharmaceuticals Inc.?
The highest price target for ETON is $52.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 107.7% increase from the current price of $25.04.
What is the lowest forecasted price for ETON Eton Pharmaceuticals Inc.?
The lowest price target for ETON is $31.00 from Madison El-Saadi at B. Riley Securities, which represents a 23.8% increase from the current price of $25.04.
What is the overall ETON consensus from analysts for Eton Pharmaceuticals Inc.?
The overall analyst consensus for ETON is bullish. Out of 5 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are ETON stock price projections?
Stock price projections, including those for Eton Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 4:10 PM UTC